Archive · 21 Jan 2026
Senores Pharma Reports 105% PAT Growth in Q3
Senores Pharmaceuticals, a company that makes medicines, had a very good third quarter in 2025.
They made a lot more money than the year before, with their profit growing by 105%.
Most of their money comes from the US, but they also have businesses in other countries and in India.
They recently bought another company, Apnar Pharmaceuticals, which helped them grow even more.
The company's leader, Swapnil Shah, said that they have a balanced business with different parts all doing well.
They are happy with how things are going and think they will keep doing well in the future.
Senores Pharmaceuticals reported a 64% year-on-year revenue growth to ₹175 crore in Q3 FY26.
Profit after tax (PAT) increased by 105% to ₹34 crore.
Regulated markets contributed 65% of total income, with revenue growing 60.5% to ₹112.7 crore.
Recent acquisition of Apnar Pharmaceuticals strengthened manufacturing and scale-up plans.
Emerging markets and branded generics in India are gaining traction and contributing positively.
- Who
- Senores Pharmaceuticals
- What
- Reported a 105% increase in profit after tax (PAT) for Q3 FY26
- When
- Third quarter ended December 31, 2025
- Where
- Global operations with a focus on the US and India
- Why
- Diversified revenue mix and strategic acquisitions
- Company
- Senores Pharmaceuticals
- Revenue Growth
- 64% year-on-year
- Profit After Tax (PAT)
- ₹34 crore (105% increase)
- Regulated Market Revenue
- ₹112.7 crore (60.5% growth)
- US Market Contribution
- 65% of total income
- Recent Acquisition
- Apnar Pharmaceuticals
- Manufacturing Locations
- US and India (FDA-approved plant)
- Business Segments
- Regulated markets, emerging markets, branded generics
